NeuroOne Medical Technologies Corporation has appointed David Wambeke as Chief Business Officer, with the executive simultaneously purchasing 1 million shares of company stock at $0.6704 per share, representing a personal investment of $670,400. This dual announcement signals strong internal conviction in NeuroOne's strategic direction as the company expands its neurological disorder treatment platform.
Wambeke will lead NeuroOne's drug delivery program and work closely with the executive team to advance clinical development and commercialization strategy. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders, and engaging prospective pharmaceutical partners to maximize the strategic value of the company's emerging drug delivery platform. He will also oversee investor relations and support strategic business development initiatives, including partnerships and corporate transactions.
"David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution," said Dave Rosa, CEO of NeuroOne. The company believes Wambeke will be instrumental in sharpening messaging, deepening investor engagement, and advancing business development activities that support long-term value creation.
Wambeke most recently served as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of the company's lead biologic into preeclampsia. He established and oversaw a first-in-pregnancy Phase 2 clinical trial that delivered positive results and contributed to substantial shareholder value creation. Prior to DiaMedica, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising public and private healthcare companies on equity financings, M&A, and strategic transactions.
"I'm excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment," said Wambeke. "With four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation in epilepsy and trigeminal nerve applications. As the Company continues to scale commercialization across these cleared indications, I believe even greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation."
NeuroOne intends to use the net proceeds from Wambeke's share purchase to support ongoing clinical and product development activities, as well as for working capital and general corporate purposes. In connection with his appointment, the company also granted Wambeke an inducement stock option to purchase 500,000 shares of common stock pursuant to the NeuroOne Medical Technologies Corporation 2021 Inducement Plan. This grant was approved by the company's compensation committee and was a material inducement to his acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of $0.6704 per share, equal to the closing price of NeuroOne's common stock on the grant date, and a 10-year term. The option will vest over four years, with 25 percent of the shares vesting on the one-year anniversary of the grant date, and the remaining shares vesting in equal quarterly installments over the remaining three years.
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. The company markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions offer the potential to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions. For more information, visit https://nmtc1.com.
